NorthWest Biotherapeutics Inc (NWBO)

[gpb]

Interesting article about the risks of adjuvant selection. For about a decade I've been fascinated by the possibilities of combination DC vaccines with immunologic adjuvants (like QS-21, inert fragments of influenza, shark liver oil, etc.) Oversimply put, if these treatments are a smart bomb, then the DC is the guidance system and the adjuvant is the +P ammo. There are many possible adjuvants and this article points out that their usefulness (or indeed, counter-productivity) depends on context. I knew some were [much] more effective than others but I did not know some (namely imiquimod) could actually be suppressive.

http://www.ncbi.nlm.nih.gov/pubmed/22510348

FWIW, there are Phase I trials getting underway using that same adjuvant with lysate-pulsed dc (not sponsored by northwest):
http://www.clinicaltrials.gov/ct2/show/NCT01808820
http://www.clinicaltrials.gov/ct2/show/NCT01902771

...just in case anyone wanted some light Sunday morning reading material.